Circulating dipeptidyl peptidase (cDPP3)-A marker for end-stage heart failure?
作者信息
Pavo Noemi, Prausmüller Suriya, Spinka Georg, Goliasch Georg, Bartko Philipp E, Arfsten Henrike, Santos Karine, Strunk Guido, Hülsmann Martin
机构信息
Department of Internal Medicine II, Clinical Division of Cardiology, Medical University of Vienna, Vienna, Austria.
4TEEN4 Pharmaceuticals GmbH, Hennigsdorf, Germany.
出版信息
J Intern Med. 2022 Jun;291(6):886-890. doi: 10.1111/joim.13449. Epub 2022 Jan 10.
Abstract
摘要
相似文献
1
Circulating dipeptidyl peptidase (cDPP3)-A marker for end-stage heart failure?
J Intern Med. 2022 Jun;291(6):886-890. doi: 10.1111/joim.13449. Epub 2022 Jan 10.
2
Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial.
JAMA Cardiol. 2018 Dec 1;3(12):1226-1231. doi: 10.1001/jamacardio.2018.3957.
3
Myocardial Angiotensin Metabolism in End-Stage Heart Failure.
J Am Coll Cardiol. 2021 Apr 13;77(14):1731-1743. doi: 10.1016/j.jacc.2021.01.052.
4
Combined neprilysin and renin-angiotensin system inhibition in heart failure with reduced ejection fraction: a meta-analysis.
Eur J Heart Fail. 2016 Oct;18(10):1238-1243. doi: 10.1002/ejhf.603. Epub 2016 Jun 30.
5
Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.
Circulation. 2016 Mar 15;133(11):1115-24. doi: 10.1161/CIRCULATIONAHA.115.018622.
6
Angiotensin-Neprilysin Inhibition as a Paradigm for All?
Curr Cardiol Rep. 2016 Nov;18(11):115. doi: 10.1007/s11886-016-0784-z.
7
Variation in use and dosing escalation of renin angiotensin system, mineralocorticoid receptor antagonist, angiotensin receptor neprilysin inhibitor and beta-blocker therapies in heart failure and reduced ejection fraction: Association of comorbidities.
Am Heart J. 2021 May;235:82-96. doi: 10.1016/j.ahj.2021.01.017. Epub 2021 Jan 23.
8
Angiotensin Receptor Neprilysin Inhibitor for Patients With Heart Failure and Reduced Ejection Fraction: Real-World Experience From Taiwan.
J Cardiovasc Pharmacol Ther. 2020 Mar;25(2):152-157. doi: 10.1177/1074248419872958. Epub 2019 Sep 12.
9
Angiotensin receptor-neprilysin inhibitor (ARNi): Clinical studies on a new class of drugs.
Int J Cardiol. 2017 Jan 1;226:136-140. doi: 10.1016/j.ijcard.2016.06.083. Epub 2016 Jun 23.
10
Chronic asymptomatic hyponatraemia following angiotensin receptor blocker-neprilysin inhibitor (ARNi) therapy: a case report.
Postgrad Med J. 2022 Mar;98(1157):165. doi: 10.1136/postgradmedj-2020-139284. Epub 2020 Dec 11.
引用本文的文献
1
Identification of an Additional Metal-Binding Site in Human Dipeptidyl Peptidase III.
Int J Mol Sci. 2023 Aug 13;24(16):12747. doi: 10.3390/ijms241612747.
2
DPP3: From biomarker to therapeutic target of cardiovascular diseases.
Front Cardiovasc Med. 2022 Oct 12;9:974035. doi: 10.3389/fcvm.2022.974035. eCollection 2022.
本文引用的文献
1
Dipeptidyl peptidase 3, a marker of the antagonist pathway of the renin-angiotensin-aldosterone system in patients with heart failure.
Eur J Heart Fail. 2021 Jun;23(6):947-953. doi: 10.1002/ejhf.2158. Epub 2021 Mar 30.
2
Circulating dipeptidyl peptidase 3 is a myocardial depressant factor: dipeptidyl peptidase 3 inhibition rapidly and sustainably improves haemodynamics.
Eur J Heart Fail. 2020 Feb;22(2):290-299. doi: 10.1002/ejhf.1601. Epub 2019 Aug 31.
3
Circulating dipeptidyl peptidase 3 and alteration in haemodynamics in cardiogenic shock: results from the OptimaCC trial.
Eur J Heart Fail. 2020 Feb;22(2):279-286. doi: 10.1002/ejhf.1600. Epub 2019 Aug 31.
4
Serum neprilysin and the risk of death in patients with out-of-hospital cardiac arrest of non-traumatic origin.
Eur Heart J Acute Cardiovasc Care. 2020 Nov;9(4_suppl):S169-S174. doi: 10.1177/2048872618815062. Epub 2018 Nov 19.
5
Recognizing worsening chronic heart failure as an entity and an end point in clinical trials.
JAMA. 2014 Aug 27;312(8):789-90. doi: 10.1001/jama.2014.6643.
Zotero 插件